Trial Profile
RANDOMIZED PHASE II TRIAL OF SHORT-COURSE ANDROGEN DEPRIVATION THERAPY +/- AVASTIN FOR PSA RECURRENCE OF PROSTATE CANCER AFTER DEFINITIVE LOCAL THERAPY. (Dana Farber 08-190).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Bicalutamide; Goserelin; Leuprorelin
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 12 Sep 2016 Status changed from active, no longer recruiting to completed.
- 12 Sep 2016 Status changed from active, no longer recruiting to completed.
- 13 Jul 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.